m+Medelevator.RU
← Поиск публикаций
JTCVS open · 2026

Robotic-assisted versus video-assisted thoracoscopic enucleation for esophageal leiomyoma: A propensity-weighted retrospective cohort study.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Xu Hengxuan, Hu Weidong

Аннотация

OBJECTIVE: The study objective was to compare recovery, operative outcomes, and direct in-hospital costs between robotic-assisted thoracic surgery and video-assisted thoracoscopic surgery for minimally invasive enucleation of esophageal leiomyoma.

METHODS: This was a single-center retrospective cohort (January 2017 to September 2025). The primary end point was postoperative length of stay. Adjusted comparisons used stabilized inverse probability of treatment weighting from a prespecified propensity score model.

RESULTS: Sixty-one patients were included (23 robotic-assisted; 38 video-assisted). In propensity-weighted analyses (robotic-assisted thoracic surgery - video-assisted thoracoscopic surgery), robotic-assisted thoracic surgery was associated with shorter postoperative length of stay (-0.85 days [-1.53 to -0.16]; P = .015), earlier chest drain removal (-0.83 days [-1.30 to -0.35]; P < .001), and lower estimated blood loss (-31.51 mL [-41.02 to -22.00]; P < .001), whereas total length of stay was similar (-0.81 days [-2.19 to 0.57]; P = .253) and direct in-hospital cost was higher (15,895 Chinese yuan [13,126-18,664; P < .001). Adverse events were infrequent. Length of stay end points were interpreted within a standardized institutional pathway.

CONCLUSIONS: In this small single-center cohort, robotic-assisted thoracic surgery was associated with shorter selected recovery milestones at higher direct in-hospital cost. These hypothesis-generating findings describe local trade-offs rather than definitive evidence of platform superiority or subgroup selection.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты